MAGE-A3

MAGE-A3 is a tumor-specific antigen belonging to the melanoma-associated antigen (MAGE) gene family. It is expressed in various cancers—including melanoma, non-small cell lung cancer (NSCLC), and head and neck cancer—but not in normal tissues except for testis. The normal function of MAGE-A3 in healthy cells remains unknown. Its presence on tumor cells has been associated with worse prognosis in some cancers[4][5]. Several investigational immunotherapeutic approaches have targeted MAGE-A3: - Recombinant protein vaccines (e.g., GSK’s “MAGE-A3 cancer immunotherapeutic”) combine purified recombinant MAGE-A3 protein with an adjuvant system to stimulate an immune response against tumors expressing this antigen[5][6][7][8]. - Peptide vaccines use specific peptides derived from the human MAGE-A3 sequence to elicit T-cell responses[3]. - Genetically modified viral vectors (e.g., adenovirus or Maraba virus) engineered to express the human MAGE-A3 gene are also under investigation as vaccine platforms[1][2]. The most advanced clinical development was by GlaxoSmithKline for adjuvant therapy of resected stage III melanoma and NSCLC; however, phase 2/phase 3 trials did not meet primary efficacy endpoints but confirmed safety profiles similar to other immunotherapies[6][7][8]. Other modalities include T-cell receptor-engineered therapies targeting the HLA-presented peptide of MAGE-A3; these have encountered safety concerns due to potential cross-reactivity with other antigens expressed at low levels in healthy tissues such as brain[10].

Other names

melanoma-associated antigen 3Melanoma antigen family A3MAGEA3 proteinMAGEA-3 proteinMAGEA 3 protein